Press release
Primary Biliary Cholangitis Treatment Market
DataM Intelligence.com
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune disorder causing progressive destruction of intrahepatic bile ducts, leading to periportal inflammation and cholestasis. This condition results in cirrhosis and portal hypertension, emphasizing the crucial role of an interprofessional team in recognizing and managing patients with PBC.
The pathogenesis of PBC is believed to involve a combination of genetic predisposition and environmental triggers. Strong familial prevalence, especially in first-degree relatives, underscores the genetic component, with a noteworthy odds ratio of 11. Notably, specific human leukocyte antigen (HLA) allele associations, such as DRB1, DR3, DPB1, DQA1, and DQB1, contribute to the understanding of PBC's genetic underpinnings.
Market Scope and Metrics:
CAGR: YY%
Size Available for Years: 2021-2030
Forecast Period: 2024-2031
Data Availability: Value (US$ Mn)
Segments Covered: Stage Type, Drug Type, Route of Administration, Distribution Channel
Regions Covered: North America, Europe, Asia-Pacific, South America, Middle East & Africa
Fastest Growing Region: Asia-Pacific
Largest Region: North America
Report Insights Cover:
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other Key Insights.
To know more Insights Download Sample : https://www.datamintelligence.com/download-sample/primary-biliary-cholangitis-treatment-market
Market Dynamics: Drivers and Restraints
The primary driver for market growth is the increasing R&D investments in developing new drug therapeutics for PBC. While there is no cure for PBC, ongoing research has led to promising treatments like seladelpar and elafibranor, currently in advanced clinical trials. Positive results from CymaBay Therapeutics Inc.'s Phase 3 pivotal RESPONSE study of seladelpar in September 2023 exemplify these advancements.
Other factors contributing to market growth include the rise in PBC prevalence, advancements in treatment, and increased awareness. However, complications associated with untreated PBC, such as osteoporosis and an increased risk of liver cancer, present restraints. Additionally, limited treatment options and lack of awareness hinder market growth.
Market Segment Analysis:
The global PBC market is segmented by stage type, drug type, route of administration, distribution channel, and region. Ursodeoxycholic acid (UDCA) dominates the drug type segment, accounting for 41.2% of the market share. It is expected to maintain this dominance throughout the forecast period.
For instance, Ipsen and GENFIT reported positive topline data from the pivotal ELATIVE Phase III trial for elafibranor in June 2023, demonstrating its efficacy and safety.
Geographical Analysis:
North America accounted for approximately 38.4% of the market share in 2022 and is projected to maintain its dominance. Factors such as a well-established healthcare infrastructure, the presence of key market players, and recent product launches contribute to the region's significant market share.
In July 2023, Gannex Pharma completed the enrollment of 98 patients with PBC in the Phase II clinical trial of ASC42, a novel Farnesoid X receptor (FXR) agonist, showcasing continued advancements in the region.
COVID-19 Impact Analysis:
The COVID-19 pandemic initially negatively impacted the PBC therapeutics industry, disrupting research activities and clinical trials. However, with the easing of lockdowns, companies have resumed operations to meet the growing demand for PBC therapeutics. Increased product approvals and research and development efforts drive market growth despite the initial setbacks.
Competitive Landscape:
Major global players in the PBC market include Intercept Pharmaceuticals, Inc., Ice Pharma, Sun Pharma, Wellona Pharma, Zoic Life Sciences, Steris Healthcare, Cadila Pharma, Cipla, Brunet, AstraEureka Pharmaceuticals, and others.
Related Reports:
metastatic breast cancer market https://www.datamintelligence.com/research-report/metastatic-breast-cancer-market
shigella vaccines pipeline market https://www.datamintelligence.com/research-report/shigella-vaccines-pipeline-market
physiological saline market https://www.datamintelligence.com/research-report/physiological-saline-market
palmar hyperhidrosis treatment market https://www.datamintelligence.com/research-report/palmar-hyperhidrosis-treatment-market
asia pacific leukemia therapeutics market https://www.datamintelligence.com/research-report/asia-pacific-leukemia-therapeutics-market
europe leukemia therapeutics market https://www.datamintelligence.com/research-report/europe-leukemia-therapeutics-market
Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Treatment Market here
News-ID: 3399143 • Views: …
More Releases from DataM Intelligence 4Market Research
Blood Clotting Factors Market Set for Breakthrough Growth Driven by Advanced Bio …
Market Overview:
The Blood Clotting Factors Market is predicted to reach at a CAGR of 6.9% during the forecast period (2024-2031).
The Blood Clotting Factors Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Blood Clotting Factors market report is an essential…
Autoimmune Treatment Market Accelerates Amid Breakthrough Therapies and Rising P …
Market Overview:
The Global Autoimmune Treatment Market is predicted to reach at a Significant CAGR during the forecast period (2024-2031).
The Autoimmune Treatment Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Autoimmune Treatment market report is an essential resource for market…
Immunology Drugs Market Poised for Breakthrough Growth Amid Rising Autoimmune an …
Market Size and Growth:
The Global Immunology Drugs Market Size reached US$ 91.97 billion in 2023 and is expected to reach US$ 148.62 billion by 2031, growing at a CAGR of 6.35% during the forecast period 2024-2031.
The Immunology Drugs Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants…
Inactivated Vaccines Market Poised for Robust Growth Amid Rising Immunization De …
Market Size and Growth:
The Global Inactivated Vaccines Market Size reached US$22.60 billion in 2024 and is expected to reach US$34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032.
The Inactivated Vaccines Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize…
More Releases for PBC
Primary Biliary Cirrhosis (PBC) Market Emerging Trends and Growth Prospects 2034
Introduction
Primary Biliary Cirrhosis (PBC), now often referred to as Primary Biliary Cholangitis, is a chronic autoimmune liver disease that slowly destroys bile ducts, leading to bile buildup, liver scarring, and eventual cirrhosis. It predominantly affects middle-aged women and is often associated with fatigue, itching, and complications that can severely impair quality of life.
With rising autoimmune disease prevalence, improved screening, and a growing focus on rare liver disorders, the global market…
Primary Biliary Cholangitis (PBC) Market Trends, Challenges and Growth Forecast
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that progressively destroys intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and eventually liver failure. The condition predominantly affects middle-aged women and is often associated with fatigue, pruritus, and elevated liver enzymes. Without effective management, PBC can result in severe complications, including portal hypertension, hepatocellular carcinoma (HCC), and the need for liver transplantation.
The PBC market has historically relied on ursodeoxycholic…
Plain Bearing Market Is Booming Worldwide |PBC Linear, Timken Company, THK
Advance Market Analytics published a new research publication on "Plain Bearing Market Insights, to 2030" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Plain Bearing market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
Sustainable Tourism Market May Set New Growth Story |Wilderness Safaris, Kind Tr …
Latest published market study on Global Sustainable Tourism Market provides an overview of the current market dynamics in the Sustainable Tourism space, as well as what our survey respondents—all outsourcing decision-makers—predict the market will look like in 2027. The study breaks market by revenue and volume (wherever applicable) and price history to estimates size and trend analysis and identifying gaps and opportunities. Some of the players that are in coverage…
Primary Biliary Cholangitis (PBC) Treatment Market is Set to Experience Revoluti …
Primary biliary cholangitis is also referred as primary biliary cirrhosis, is an autoimmune disease of liver that manifest into progressive cholestasis and lead to end-stage liver disease. Primary biliary cholangitis characterized by destruction of bile duct which transport the bile acid. Primary biliary cholangitis is detected in the late stage of disease. Primary biliary cirrhosis majorly seen in women’s in fourth or sixth decades of life. Primary biliary cholangitis generally…
Primary Biliary Cholangitis (PBC) Treatment Market : Analysis And Forecast (2016 …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
